WHAT IS CLAIMED IS:

1. A compound selected from 2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one and pharmaceutically acceptable salts thereof.

2. A compound selected from (S)-2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one and pharmaceutically acceptable salts thereof.

3. The compound according to claim 2, wherein the compound is substantially free of (R)-2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one, and pharmaceutical acceptable salts thereof.

4. The compound of claim 2, wherein the compound has an enantiomeric excess greater than about 95%.

5. (S)-2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one.

6. The compound of claim 5, wherein the compound is substantially free of (R)-2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one.

7. The compound of claim 5, wherein the compound has an enantiomeric excess greater than about 95%.

8. A pharmaceutical composition comprising a compound according to any one of claims 1-7 and at least one pharmaceutically acceptable carrier.

9. A method of inhibiting a catalytic activity of a PI3 δ kinase present in a cell, comprising contacting the cell with an effective amount of a compound according to any one of claims 1-7.

10. A method of inhibiting a catalytic activity of a PI3 γ kinase present in a cell, comprising contacting the cell with an effective amount of a compound according to any one of claims 1-7.

11. A method of inhibiting a catalytic activity of a PI3 δ kinase and PI3 γ kinase present in a cell, comprising contacting the cell with an effective amount of a compound according to any one of claims 1-7.

12. The method of any one of claims 9-11, wherein the inhibition takes place in a subject suffering from a disease, disorder or condition selected from cancer, a bone disorder, an inflammatory disease, an immune disease, a nervous system disease, a metabolic disease, a respiratory disease, thrombosis, and cardiac disease.

13. A method of treating leukemia in a patient in need thereof, the method comprising administering an effective amount of a compound of any one of claims 1-7.

14. A method of treating asthma or chronic obstructive pulmonary disease in a patient in need thereof, the method comprising administering an effective amount of a compound of any one of claims 1-7.

15. A method of treating rhematoid arthritis, psorias, lupus or experimental autoimmune encephalomyelitis (EAE) in a patient in need thereof, the method comprising administering an effective amount of a compound of any one of claims 1-7.

16 A method of treating chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL) acute myeloid leukemia (AML), multiple myeloma (MM), small lymphocytic lymphoma (SLL), or indolent non-Hodgkin's lymphoma (I-NHL) disease in a patient in need thereof, the method comprising administering an effective amount of a compound of any one of claims 1-7.

17. Use of a compound of any one of claims 1-7, in the manufacture of a medicament for the treatment of a disease, disorder or condition that would benefit from inhibiting catalytic activity of a PI3 δ/γ kinase.

18. A method for the treatment of a PI3K associated disease, disorder or condition comprising administering to a subject in need thereof an effective amount of the compound of any one of claims 1-7.

19. The method of claim 18, further comprising administering an additional active agent selected from anti-cancer agents, anti-inflammatory agents, immunosuppressive agents, steroids, non-steroidal anti-inflammatory agents, antihistamines, analgesics, and mixtures thereof.

20. The method of claim 18, wherein the PI3K associated disease, disorder or condition is an immune system-related disease, a disease or disorder involving inflammation, cancer or other proliferative disease, a hepatic disease or disorder, or a renal disease or disorder.

21. The method of claim 18, wherein the PI3K associated disease, disorder or condition is selected from leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkins lymphoma, hairy cell lymphoma, Burkett's lymphoma, acute and chronic myelogenous leukemias, myelodysplastic syndrome and promyelocytic leukemia, psoriasis, rheumatoid arthritis, osteoarthritis, asthma, COPD , allergic rhinitis and lupus erythematosus.

WHAT IS CLAIMED IS:

1. A compound selected from 2-(l-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one and pharmaceutically acceptable salts thereof.

2. A compound selected from (S)-2-(l-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one and pharmaceutically acceptable salts thereof.

3. The compound according to claim 2, wherein the compound is substantially free of (R)-2-(l-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one, and pharmaceutical acceptable salts thereof.

4. The compound of claim 2, wherein the compound has an enantiomeric excess greater than about 95%.

5. (S)-2-(l-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one.

6. The compound of claim 5, wherein the compound is substantially free of (R)-2-(l-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one.

7. The compound of claim 5, wherein the compound has an enantiomeric excess greater than about 95%.

8. A pharmaceutical composition comprising a compound according to any one of claims 1-7 and at least one pharmaceutically acceptable carrier.

9. A method of inhibiting a catalytic activity of a PI3 δ kinase present in a cell, comprising contacting the cell with an effective amount of a compound according to any one of claims 1-7.

10. A method of inhibiting a catalytic activity of a PI3 γ kinase present in a cell, comprising contacting the cell with an effective amount of a compound according to any one of claims 1-7.

11. A method of inhibiting a catalytic activity of a PI3 δ kinase and PI3 γ kinase present in a cell, comprising contacting the cell with an effective amount of a compound according to any one of claims 1-7.

12. The method of any one of claims 9-11, wherein the inhibition takes place in a subject suffering from a disease, disorder or condition selected from cancer, a bone disorder, an inflammatory disease, an immune disease, a nervous system disease, a metabolic disease, a respiratory disease, thrombosis, and cardiac disease.

13. Use of a compound of any one of claims 1-7, in the manufacture of a medicament for the treatment of a disease, disorder or condition that would benefit from inhibiting catalytic activity of a PI3 δ /γ kinase.